Sequence Conversion Reaction Patent - Rosalind DX

The European Patent Office published patent application EP4165184A2 for Sequence Conversion Reaction technology filed by Rosalind DX Pte. Ltd. The patent covers molecular diagnostic methods with applications in genetic analysis and biotechnology. The A2 publication indicates the application has passed formal examination and is open for third-party opposition.

Synthetic Mixed Culture Resembling a Skin Microbiome

The European Patent Office published patent application EP4256341A1 for Evonik Operations GmbH covering a synthetic mixed culture resembling a skin microbiome. The invention relates to G01N 33/569, C12N 1/20, and A61K 35/00 classifications, with inventors Blattert and Lersch. The patent designates all EU member states plus several additional European countries.

Uniform Cell Aggregate Mass Production Method

The European Patent Office published patent application EP4159838A1 filed by Orizuru Therapeutics, Inc. and Toyo Seikan Group Holdings, Ltd. for a mass production method of uniform-sized cell aggregates. The application was formally examined and designates all 38 EPO member states and extension countries. This biotechnological innovation has applications in regenerative medicine, drug discovery screening, and tissue engineering.

Protease-Activating CD45-Gate CAR for Cancer Treatment

The European Patent Office published patent application EP4263590A1 for Allogene Therapeutics and Pfizer's protease-activating CD45-gate chimeric antigen receptor (CAR) technology for cancer treatment. The patent covers engineered T-cells with protease-activated gating mechanisms and applications in oncology.

Inventory Management with Automatic Alignment of Balances Across Multiple Orthogonal Categorization Schemes

The EPO published patent application EP4546235A1 filed by MUREX S.A.S. for an inventory management system that automatically aligns balances across multiple orthogonal categorization schemes. The patent application was published on March 25, 2026. Designated states include EU member states and the United Kingdom.

Vehicle Routing Problem Solution Using Annealer-Based Solvers

The European Patent Office published patent application EP4336427A1 for Fujitsu Limited, covering a vehicle routing problem (VRP) solution using annealer-based solvers for optimized logistics. The invention, classified under G06Q 10/047, was filed by inventors Ushijima-Mwesigwa, Shati, and Ghosh. The patent application designates all major European states including DE, FR, GB, IT, NL, ES, and others.

Prosthetic Valves and Sensor Systems Patent Application

The European Patent Office published patent application EP4633534A1 for prosthetic valves and sensor systems filed by Edwards Lifesciences Corporation. The application covers cardiac valve replacement technology including sensor systems for monitoring valve function. The patent is classified under A61F 2/24 (heart valves) with designations extending across 44 European Contracting States.

CAR Specific to MUC18 for Cancer Therapy

The European Patent Office published application EP3898698A1 for Multitude Therapeutics Co., Ltd., covering a Chimeric Antigen Receptor (CAR) specific to MUC18 for cancer therapy. The application includes inventors HOU, Bing, CHEN, Peng, LIU, Junli, MENG, Xun, and LIU, Shu-Hui. Designated states include all EU member states plus associated countries.

Integrated Drug Discovery Platform for Inborn Error Disorders

The European Patent Office published patent application EP3894578A1 by Ramot at Tel-Aviv University Ltd. for an integrated drug discovery platform targeting inborn errors of metabolism disorders. The platform covers methods using compounds classified under A61K31/122 and A61K31/352, with applications in metabolic disorder treatment. Designated states include all current EU member states plus extension states.

Myosin 15 Promoters and Uses Thereof

The European Patent Office published patent application EP3784289A1 for Decibel Therapeutics' Myosin 15 promoters and their therapeutic uses in hearing loss treatment. The application covers gene therapy compositions targeting myosin 15 expression for the treatment of hearing disorders. The patent is designated across 35 European member states including DE, FR, GB, IT, ES, NL, and others.